Extended Release Naltrexone Versus Extended Release Buprenorphine with Individuals Leaving Jail

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 28, 2020

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Opioid-use Disorder
Interventions
DRUG

XR-B

Individuals will receive extended-release buprenorphine, administered as a subcutaneous injection, is available in seven different dosage strengths for weekly (8, 16, 24, and 32 mg) and monthly (64, 96, and 128 mg) administration by a health care professional.

DRUG

XR-NTX

Injectable naltrexone will be used, at a dose of 4cc (380mg of naltrexone), administered by intramuscular injection to the buttocks (alternating sides monthly). Individuals will receive monthly injections.

Trial Locations (1)

21201

Friends Research Institute, Baltimore

All Listed Sponsors
lead

Friends Research Institute, Inc.

OTHER